Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan monotherapy in advanced PPGL, pNET, VHL-associated tumors, wild-type GIST, and solid tumors with HIF-2α-related alterations
NL-OMON53900Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), islet cell tumor and 4 more (3 cohorts), sponsored by Merck & Co. Primary endpoints: Objective response rate, Objective response rate in VHL disease-associated PPGL and 2 more. Started Apr 2023; status: recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)islet cell tumorvon Hippel–Lindau disease (VHL)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON53900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53900.